Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.
1. An isolated antibody which binds to human Tissue Factor (TF), wherein the isolated antibody comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain complementarity determining regions (CDRs) (VL-CDR1, VL-CDR2, and VL-CDR3), wherein the VH-CDR1, VH-CDR2, and VH-CDR3 are from a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO:836, and wherein the VL-CDR1, VL-CDR2, and VL-CDR3 are from a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO:837.
2. An isolated antibody which binds to human TF and comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain CDRs (VL-CDR1, VL-CDR2, and VL-CDR3), wherein: the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 890, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 891, and the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 892, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 893, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 894, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:895, and wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are defined according to the Kabat numbering system.
3. The isolated antibody of claim 1 , wherein
(i) the isolated antibody binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa the isolated antibody binds to the extracellular domain; and
(ii) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;
the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;
the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;
the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;
the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;
the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; or
the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,
as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
4. The isolated antibody of claim 1 , wherein the antibody:
(i) binds to cynomolgus TF;
(ii) binds to rabbit TF; and
(iii) binds to pig TF.
5. The isolated antibody of claim 1 , wherein the antibody:
(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);
(b) allows human thrombin generation as determined by thrombin generation assay (TGA);
(c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;
(d) does not interfere with the ability of TF:FVIIa to convert FX into FXa;
(e) does not compete for binding to human TF with FVIIa; and
(f) inhibits FVIIa-dependent TF signaling.
6. The isolated antibody of claim 1 , wherein the antibody:
(a) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;
(b) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;
(c) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;
(d) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;
(e) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; and
(f) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.
7. The isolated antibody of claim 1 , wherein the antibody reduces lesion size in a swine choroidal neovascularization (CNV) model.
8. The isolated antibody of claim 1 , wherein the antibody binds to human TF with a K D of less than or equal to 50 nM, as measured by Octet QK384 or Biacore assay.
9. The isolated antibody of claim 1 , wherein the antibody is human, humanized, or chimeric.
10. The isolated antibody of claim 1 , wherein the antibody is a monoclonal antibody.
11. The isolated antibody of claim 1 , wherein the antibody is multispecific.
12. The isolated antibody of claim 1 , wherein the antibody is a Fab, Fab′, F(ab′)2, Fv, scFv, (scFv)2, single chain antibody molecule, dual variable domain antibody, linear antibody, or V domain antibody.
13. The isolated antibody of claim 1 , wherein the antibody comprises an Fc region.
14. The isolated antibody of claim 1 , wherein:
(i) the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM, or
(ii) the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.
15. The isolated antibody of claim 2 , wherein:
(i) the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM, or
(ii) the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.
16. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain constant region of human IgG1.
17. The isolated antibody of claim 2 , wherein the antibody comprises a heavy chain constant region of human IgG1.
18. A pharmaceutical composition comprising (i) the isolated antibody of claim 1 and (ii) a pharmaceutically acceptable excipient.
19. A kit comprising the isolated antibody of claim 1 and instructions for use.
20. The isolated antibody of claim 1 , wherein the sequence of the VH comprises the amino acid sequence set forth in SEQ ID NO:836, and the sequence of the VL comprises the amino acid sequence set forth in SEQ ID NO:837.
21. The isolated antibody of claim 1 , wherein the sequence of the VH consists of the amino acid sequence set forth in SEQ ID NO:836, and the sequence of the VL consists of the amino acid sequence set forth in SEQ ID NO:837.
22. The isolated antibody of claim 20 , wherein the antibody comprises a heavy chain constant region of human IgG1.
23. The isolated antibody of claim 21 , wherein the antibody comprises a heavy chain constant region of human IgG1.
24. A pharmaceutical composition comprising (i) the isolated antibody of claim 20 and (ii) a pharmaceutically acceptable excipient.
25. A pharmaceutical composition comprising (i) the isolated antibody of claim 21 and (ii) a pharmaceutically acceptable excipient.
26. A pharmaceutical composition comprising (i) the isolated antibody of claim 22 and (ii) a pharmaceutically acceptable excipient.
27. A pharmaceutical composition comprising (i) the isolated antibody of claim 23 and (ii) a pharmaceutically acceptable excipient.
28. The isolated antibody of claim 2 , wherein the sequence of the VH comprises the amino acid sequence set forth in SEQ ID NO:836, and the sequence of the VL comprises the amino acid sequence set forth in SEQ ID NO:837.
29. The isolated antibody of claim 2 , wherein the sequence of the VH consists of the amino acid sequence set forth in SEQ ID NO:836 and the sequence of the VL consists of the amino acid sequence set forth in SEQ ID NO:837.
30. The isolated antibody of claim 28 , wherein the antibody comprises a heavy chain constant region of human IgG1.
31. The isolated antibody of claim 29 , wherein the antibody comprises a heavy chain constant region of human IgG1.
32. A pharmaceutical composition comprising (i) the isolated antibody of claim 28 and (ii) a pharmaceutically acceptable excipient.
33. A pharmaceutical composition comprising (i) the isolated antibody of claim 29 and (ii) a pharmaceutically acceptable excipient.
34. A pharmaceutical composition comprising (i) the isolated antibody of claim 30 and (ii) a pharmaceutically acceptable excipient.
35. A pharmaceutical composition comprising (i) the isolated antibody of claim 31 and (ii) a pharmaceutically acceptable excipient.
36. The isolated antibody of claim 1 , wherein the antibody binds to human TF with a K D of less than or equal to 10 nM, as measured by Octet QK384 or Biacore assay.
37. The isolated antibody of claim 1 , wherein the antibody binds to human TF with a K D of less than or equal to 5 nM, as measured by Octet QK384 or Biacore assay.
38. The isolated antibody of claim 1 , wherein the antibody binds to human TF with a K D of less than or equal to 1 nM, as measured by Octet QK384 or Biacore assay.
39. The isolated antibody of claim 1 , wherein the antibody binds to human TF with a K D of less than or equal to 0.5 nM, as measured by Octet QK384 or Biacore assay.
40. The isolated antibody of claim 1 , wherein the antibody binds to human TF with a K D of less than or equal to 0.1 nM, as measured by Octet QK384 or Biacore assay.